VivoSeq
Oncology

Extensive-Stage Small-Cell Lung Cancer

18

Pipeline Programs↗

7

Active Trials↗

12

Companies Involved↗

Extensive-stage Small-cell Lung Cancer is an emerging landscape with 18 programs across 12 companies. The most active players are Sanofi, AstraZeneca, Amgen. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

6/100

Mech. Concentration

11/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1AstraZeneca logo

AstraZeneca

2 programs

Phase 2Amgen logo

Amgen

1 program

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2S

Summit Therapeutics

1 program

Phase 2Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

63%

Small molecule

12 of 19 classified programs — the dominant modality here.

37%ALL OTHERSMonoclonal antibody526%Cell therapy15%Vaccine15%

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 90% of 21 pipeline programs.

Analysis

Trial Status

12

clinical trials

Completed5 · 42%
Active, not recruiting3 · 25%
Recruiting3 · 25%
Not yet recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer
Recruiting·BioNTech logoBioNTech·Phase 3·NCT06712355·621 enrolled
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT06646276·530 enrolled
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Recruiting·Amgen logoAmgen·Phase 1·NCT06598306·220 enrolled
A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363
Active, not recruiting·—·Phase 2·NCT04699838·30 enrolled
Phase 2a Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of Tarlatamab in Chinese Subjects With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-307)
Active, not recruiting·Amgen logoAmgen·Phase 2·NCT06502977·32 enrolled
A Phase II Study of MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Active, not recruiting·GGeorgetown University·Phase 2·NCT06227546·9 enrolled
A Phase I Study to Assess the Safety and Antitumor Activity of Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
Not yet recruiting·National Cancer Institute (NCI)·Phase 1·NCT07509034·40 enrolled
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Completed·NRG Oncology·Preclinical·NCT02635009·418 enrolled
Phase Ib/II Trial of the Combination of Atezolizumab With Dendritic Cell Vaccination as Maintenance Treatment in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) After Induction Treatment
Completed·IInstituto Oncológico Dr Rosell·Preclinical·NCT04487756·20 enrolled
Phase II Study of AK112 Combined With Irinotecan Liposome in Patients With SCLC Who Progressed on Immune Checkpoint Inhibitors and Chemotherapy.
Completed·ZZhejiang Cancer Hospital·Phase 2·NCT06478043·60 enrolled
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT00887159·168 enrolled
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Completed·National Cancer Institute (NCI)·Preclinical·NCT01642251·156 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)